Outlook Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Outlook Therapeutics

14/08/2026 14:31

Outlook Therapeutics Inc OTLK.OQ reported a quarterly adjusted loss of 9 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -55 cents.  The mean expectation of four analysts for the quarter was for a loss of 9 cents per share. Wall Street expected results to range from -11 cents to -5 cents per share.
Revenue fell 99.4% to $9.00 thousand from a year ago; analysts expected $5.30 million. 
Outlook Therapeutics Inc's reported EPS for the quarter was a loss of 15 cents​.
The company reported a quarterly loss of $20.32 million.
Outlook Therapeutics Inc shares had fallen by 44.1% this quarter and lost 43.7% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 18.7% in the last three months.​ 
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Outlook Therapeutics Inc is $5.00, about 82.2% above its last closing price of $0.89
This summary was machine generated from LSEG data August 14 at 01:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.09
-0.09
Met
Mar. 31 2026 
-0.12
-0.16
Missed
Dec. 31 2025 
-0.17
-0.22
Missed
Sep. 30 2025 
-0.25
-0.19
Beat